• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/25 4:11:02 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    0001847367false00018473672025-05-142025-05-14

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2025

    Alumis Inc.

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

        

    001-42143

        

    86-1771129

    (State or other jurisdiction
    of incorporation)

     

    (Commission
    File Number)

     

    (IRS Employer
    Identification No.)

    ​

    280 East Grand Avenue

    South San Francisco, California 94080

    (Address of principal executive offices)

    Registrant’s telephone number, including area code: (650) 231-6625

    N/A

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading
    Symbol(s)

        

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share

     

    ALMS

     

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

    ​

    ​

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition.

    On May 14, 2025, Alumis Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

    All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    ​

    Item 9.01 Financial Statements and Exhibits.

    (d)Exhibits.

    ​

    Exhibit No.

        

    Description

    99.1

    Press Release, dated May 14, 2025

    104

      

    Cover Page Interactive Data File (embedded within the Inline XBRL Document)

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    Alumis Inc.

    ​

    ​

    ​

    By:

    /s/ Martin Babler

    ​

    ​

    Martin Babler

    ​

    ​

    President and Chief Executive Officer

    ​

    Dated: May 14, 2025

    ​

    Get the next $ALMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    6/10/2025$18.00Buy
    Guggenheim
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    7/23/2024Overweight
    Cantor Fitzgerald
    7/23/2024$29.00Outperform
    Leerink Partners
    7/23/2024$32.00Buy
    Guggenheim
    7/23/2024$36.00Overweight
    Morgan Stanley
    More analyst ratings

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alumis to Present at the Jefferies Global Healthcare Investor Conference

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on the company's website for 90 days. About Alumis Alumis is a late-stage biopharma company developing next-generation targeted therapies with the pot

      5/29/25 4:15:56 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program of ESK-001 for the treatment of moderate-to-severe plaque psoriasis. "We are excited to announce the completion of patient enrollment in our pivotal Phase 3 ONWARD clinical program evaluating ESK-001 for moderate-to-severe plaque psoriasis," said Martin Babler, President and Chief Executive Officer of Alumis. "With over 1,700 patients enrolled across the two trials, this milestone ref

      5/29/25 7:55:00 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Completes Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. "We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis' differentiated late-stage portfolio and develop transformative th

      5/21/25 9:10:51 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Alumis with a new price target

      Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00

      6/10/25 8:07:01 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Alumis with a new price target

      Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

      1/30/25 7:47:22 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Alumis with a new price target

      Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

      10/31/24 6:14:08 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tananbaum James B. bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:59 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Labs, Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:12 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Capital Management Vi Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:47:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Akkaraju Srinivas was granted 1,214,582 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 8:47:53 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ayurmaya Capital Management Company, Lp was granted 4,493,741 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:20:51 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Machado Patrick was granted 7,064 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:05:20 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    SEC Filings

    See more
    • SEC Form S-8 filed by Alumis Inc.

      S-8 - ALUMIS INC. (0001847367) (Filer)

      6/10/25 4:46:36 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 8:49:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 4:16:27 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Financials

    Live finance-specific insights

    See more
    • Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

      2/6/25 4:15:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      8/27/24 4:20:38 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alumis Inc.

      SC 13G - ALUMIS INC. (0001847367) (Subject)

      7/11/24 4:30:21 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      7/5/24 9:30:17 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care